Literature DB >> 26885189

Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors.

Maonan Wang1, Xin Xia2, Wenxiang Chu1, Liyan Xia1, Tao Meng1, Lintao Liu1, Yushi Liu1.   

Abstract

OBJECTIVES: This work aims to investigate the expression of miRNA-186 in patients with colorectal cancer tissues, blood and feces and its roles in regulating the infiltration and invasion in colorectal cancer.
METHODS: Totally 39 patients with surgical resection were included from August 2012 to February 2015 in Jilin Province People's Hospital as the Colorectal Neuroendocrine tumor (CNET). Peripheral blood, stool, and resected tumor tissues with adjacent normal of each patient was collected. In the same period, the blood and stool from 25 patients with hemorrhoids or other non-neoplastic diseases were collected and these samples used as clinical control group. MiR-186 expression and PTTG1 (pituitary tumor-transforming 1) expression were detected by quantitative Real-Time PCR (qRT-PCR). The PTTG1 protein expression in tumor samples were detected by Western Blot, while its expression in blood and stool were detected by Elisa.
RESULTS: Compared with the control group, the expression of PTTG1 mRNA and protein was significantly up-regulated in tumor samples, blood, and stool of patients with CNET, while the expression of miR-186 was down-regulated (P < 0.05).
CONCLUSION: PTTG1 expression was significantly up-regulated in patients with CNET, which was induced by the down-regulated miR-186. MiR-186 may participate in the regulation of infiltration and invasion in CNET patients through targeting PTTG1 expression.

Entities:  

Keywords:  CNET; PTTG1; colorectal neuroendocrine tumor; miRNA-186

Year:  2015        PMID: 26885189      PMCID: PMC4729975     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  35 in total

Review 1.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

2.  Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).

Authors:  X Zhang; G A Horwitz; T R Prezant; A Valentini; M Nakashima; M D Bronstein; S Melmed
Journal:  Mol Endocrinol       Date:  1999-01

3.  miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts.

Authors:  Pan Sun; Jun-Wei Hu; Wu-Jun Xiong; Jun Mi
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG).

Authors:  S S Kakar
Journal:  Gene       Date:  1999-11-29       Impact factor: 3.688

5.  Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells.

Authors:  Li Ning; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

6.  The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.

Authors:  J A C Hunter; R H Skelly; S J B Aylwin; J F Geddes; J Evanson; G M Besser; J P Monson; J M Burrin
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing.

Authors:  Julian Hamfjord; Astrid M Stangeland; Timothy Hughes; Martina L Skrede; Kjell M Tveit; Tone Ikdahl; Elin H Kure
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

9.  Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells.

Authors:  Young-Hoon Lee; Soo Young Kim; Young-Seuk Bae
Journal:  Mol Cells       Date:  2014-08-19       Impact factor: 5.034

10.  miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.

Authors:  Zheng-liang Zhang; Zheng-hai Bai; Xiao-bo Wang; Ling Bai; Fei Miao; Hong-hong Pei
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

View more
  6 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  PTTG3P promotes gastric tumour cell proliferation and invasion and is an indicator of poor prognosis.

Authors:  Weiwei Weng; Shujuan Ni; Yiqin Wang; Midie Xu; Qiongyan Zhang; Yusi Yang; Yong Wu; Qinghua Xu; Peng Qi; Cong Tan; Dan Huang; Ping Wei; Zhaohui Huang; Yuqing Ma; Wei Zhang; Weiqi Sheng; Xiang Du
Journal:  J Cell Mol Med       Date:  2017-06-19       Impact factor: 5.310

3.  miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1.

Authors:  Chunhong Cao; Deguang Sun; Liang Zhang; Lei Song
Journal:  Oncotarget       Date:  2016-11-29

Review 4.  Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.

Authors:  Annamaria Colao; Filomena de Nigris; Roberta Modica; Claudio Napoli
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-15       Impact factor: 5.555

Review 5.  Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.

Authors:  Michele Prisciandaro; Maria Antista; Alessandra Raimondi; Francesca Corti; Federica Morano; Giovanni Centonze; Giovanna Sabella; Alessandro Mangogna; Giovanni Randon; Filippo Pagani; Natalie Prinzi; Monica Niger; Salvatore Corallo; Erica Castiglioni di Caronno; Marco Massafra; Maria Di Bartolomeo; Filippo de Braud; Massimo Milione; Sara Pusceddu
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

6.  Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.

Authors:  Simona Caporali; Ester Alvino; Pedro Miguel Lacal; Federica Ruffini; Lauretta Levati; Laura Bonmassar; Alessandro Scoppola; Paolo Marchetti; Simona Mastroeni; Gian Carlo Antonini Cappellini; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.